The ‘Angelina Jolie effect’
Intended for healthcare professionals
Research focus Previous     Next

The ‘Angelina Jolie effect’

Caroline McGraw Lecturer, Public health, School of Health Sciences, City, University of London

Inherited mutations in the known breast cancer susceptibility genes (BRCA1 and BRCA2) are associated with an increased risk of developing breast and ovarian cancer. In May 2013, Angelina Jolie disclosed she was a carrier of one of these mutations and announced she had undergone a preventive bilateral mastectomy (PBM). Two years later, she announced she had undergone a laparoscopic bilateral salpingo-oophorectomy. This research digest summarises three recent studies evaluating the effect of her disclosure.

Primary Health Care. 28, 1, 14-14. doi: 10.7748/phc.28.1.14.s13

Want to read more?

RCNi-Plus
Already have access? Log in

or

3-month trial offer for £5.25/month

Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
  • Unlimited access to all 10 RCNi Journals
  • RCNi Learning featuring over 175 modules to easily earn CPD time
  • NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
  • Personalised newsletters tailored to your interests
  • A customisable dashboard with over 200 topics
Subscribe

Alternatively, you can purchase access to this article for the next seven days. Buy now


Are you a student? Our student subscription has content especially for you.
Find out more